Storia in 4 fonti

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.

Raccontata dazerohedge.combenzinga.cominvestors.commorningstar.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 g fa

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.

originale

morningstar.com2 g fa

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics launches $500M public offering to fund DT120 ODT, a psychedelic-assisted therapeutic for psychiatric and neurological disorders. The capital raise signals biotech-backed psychedelic therapy as an emerging market category for healthcare-focused investors.

Leggi questa versione → originale

zerohedge.com3 g fa

Psychedelic Stocks Could Explode Higher

Definium's DT120 met Phase 3 for LSD-based depression therapy, driving DFTX +200% YTD with single-dose efficacy versus SSRIs. Policy-driven FDA expedited pathway opens M&A consolidation window; psychedelic therapeutics signal broader deregulation trend in healthcare.

Leggi questa versione → originale

investors.com3 g fa

Biotech Goes Sky-High After LSD Drug Treats Depression

One analyst called this a "best-case" scenario for the company's experimental depression treatment.

Leggi questa versione → originale

Timeline cronologica

1. lunedì 22 giugno 2026·zerohedge.com
   

   Psychedelic Stocks Could Explode Higher

   Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...

2. lunedì 22 giugno 2026·benzinga.com
   

   Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

   Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…

3. lunedì 22 giugno 2026·investors.com
   

   Biotech Goes Sky-High After LSD Drug Treats Depression

   One analyst called this a "best-case" scenario for the company's experimental depression treatment.

4. lunedì 22 giugno 2026·zerohedge.com
   

   Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

   DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.

5. lunedì 22 giugno 2026·morningstar.com
   

   Definium Therapeutics, Inc. Announces Proposed Public Offering

   Definium Therapeutics, Inc. Announces Proposed Public Offering

6. martedì 23 giugno 2026·benzinga.com
   

   What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

   Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.

7. mercoledì 24 giugno 2026·morningstar.com
   

   Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

   Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering